Pfizer Inc (PFE) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. (PFE) is launching a phase 2 study called “A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER.” The goal is to test safety and immune response of new mRNA flu shots in healthy adults, an important step in expanding Pfizer’s vaccine portfolio beyond COVID.
The study tests six mRNA flu vaccine candidates and compares them with an approved flu shot. All products are given as a single shot in the arm and are designed to protect against the influenza virus while aiming for a faster and more flexible development model than traditional flu vaccines.
This is an interventional phase 2 trial where adults are randomly placed into groups that receive one of the six mRNA shots or a standard licensed flu vaccine. The study is double-blind, so neither participants nor investigators know who gets which shot, and the main aim is to prevent flu by checking both safety and the strength of the immune response.
The trial is listed as not yet recruiting, with first submission on 19 Feb 2026 and the latest update on 25 Feb 2026, showing an active setup phase. Primary completion and final end dates are not yet posted, which signals that investors should view this as an early- to mid-stage, multi-year program rather than a near-term revenue driver.
For PFE, this update reinforces its push to build a durable vaccine franchise using mRNA beyond COVID, which could support long-term growth expectations if results are strong. It also positions Pfizer in direct competition with Moderna, Sanofi, and GSK in the future flu market, and positive early signals from this study could improve sentiment on PFE’s pipeline value and help support the stock during a period of post-COVID revenue reset.
The study is currently in the setup phase and remains active on the ClinicalTrials portal, where further details and future updates will be posted as the trial progresses.
To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.